{"id":"placebo-for-remdesivir","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Placebos are inert substances used as controls in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to natural disease progression, regression to the mean, or the placebo effect (psychological/expectation-based response). In this context, the placebo serves as the control arm in a Phase 3 trial comparing remdesivir efficacy.","oneSentence":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:51:26.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in remdesivir clinical trials (likely COVID-19 or viral respiratory infection)"}]},"trialDetails":[{"nctId":"NCT07013474","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-07-14","conditions":"COVID-19 Infection","enrollment":300},{"nctId":"NCT04746183","phase":"PHASE1, PHASE2","title":"AGILE (Early Phase Platform Trial for COVID-19)","status":"RECRUITING","sponsor":"University of Liverpool","startDate":"2020-07-03","conditions":"Covid19","enrollment":600},{"nctId":"NCT04843761","phase":"PHASE3","title":"ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":473},{"nctId":"NCT06729593","phase":"PHASE3","title":"Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-20","conditions":"Covid19","enrollment":87},{"nctId":"NCT06860282","phase":"PHASE1","title":"A Study of CX2101A Enteric-Coated Tablets in Healthy Chinese Adult Subjects","status":"COMPLETED","sponsor":"Heronova Pharmaceuticals","startDate":"2022-12-26","conditions":"COVID-19, Coronavirus Pneumonia","enrollment":63},{"nctId":"NCT05780437","phase":"PHASE3","title":"AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-02-10","conditions":"COVID-19","enrollment":1455},{"nctId":"NCT06792214","phase":"PHASE4","title":"Antiviral Strategies in the Prevention of Long-term Cardiovascular Outcomes Following COVID-19: The paxloviD/Remdesivir Effectiveness For the prEvention of loNg coviD Clinical Trial","status":"RECRUITING","sponsor":"Mount Sinai Hospital, Canada","startDate":"2025-01-03","conditions":"SARS CoV-2 Post-Acute Sequelae","enrollment":118},{"nctId":"NCT04315948","phase":"PHASE3","title":"Trial of Treatments for COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2020-03-22","conditions":"Corona Virus Infection","enrollment":1552},{"nctId":"NCT05038488","phase":"PHASE2","title":"Phase 2a MIB-626 vs. Placebo COVID-19","status":"COMPLETED","sponsor":"Metro International Biotech, LLC","startDate":"2021-10-26","conditions":"Covid19, Stage 1 Acute Kidney Injury","enrollment":42},{"nctId":"NCT05780541","phase":"PHASE3","title":"PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-09-15","conditions":"COVID-19","enrollment":58},{"nctId":"NCT05780424","phase":"PHASE3","title":"BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-16","conditions":"COVID-19","enrollment":353},{"nctId":"NCT05780463","phase":"PHASE3","title":"MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-06-11","conditions":"COVID-19","enrollment":485},{"nctId":"NCT05780281","phase":"PHASE3","title":"VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-16","conditions":"COVID-19","enrollment":367},{"nctId":"NCT05780268","phase":"PHASE3","title":"LY3819253 (LY-CoV555) for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-05","conditions":"COVID-19","enrollment":314},{"nctId":"NCT04593940","phase":"PHASE3","title":"Immune Modulators for Treating COVID-19","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2020-10-15","conditions":"Covid19","enrollment":1971},{"nctId":"NCT05407597","phase":"PHASE2, PHASE3","title":"Inhibition of Bradykinin in COVID-19 Infection With Icatibant","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2022-05-16","conditions":"SARS CoV 2 Infection","enrollment":32},{"nctId":"NCT04501978","phase":"PHASE3","title":"ACTIV-3: Therapeutics for Inpatients With COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-04","conditions":"Covid19","enrollment":2753},{"nctId":"NCT04391309","phase":"PHASE2","title":"COVID-19 and Anti-CD14 Treatment Trial","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-04-12","conditions":"Coronavirus Disease 2019 (COVID-19), Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)","enrollment":49},{"nctId":"NCT04988035","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-08-03","conditions":"COVID-19","enrollment":201},{"nctId":"NCT04583969","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-23","conditions":"COVID-19","enrollment":527},{"nctId":"NCT04583956","phase":"PHASE2","title":"ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-10-23","conditions":"COVID-19","enrollment":214},{"nctId":"NCT04745351","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2021-03-31","conditions":"COVID-19","enrollment":249},{"nctId":"NCT04672564","phase":"PHASE3","title":"Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients","status":"TERMINATED","sponsor":"Shenyang Tonglian Group CO., Ltd","startDate":"2021-03-30","conditions":"Coronavirus Disease 2019","enrollment":93},{"nctId":"NCT04640168","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 4 (ACTT-4)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-02","conditions":"COVID-19","enrollment":1010},{"nctId":"NCT04546581","phase":"PHASE3","title":"Inpatient Treatment of COVID-19 With Anti-Coronavirus Immunoglobulin (ITAC)","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2020-10-08","conditions":"COVID, COVID-19, SARS-CoV-2","enrollment":593},{"nctId":"NCT04492475","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 3 (ACTT-3)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-08-05","conditions":"COVID-19","enrollment":969},{"nctId":"NCT04280705","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial (ACTT)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-02-21","conditions":"COVID-19","enrollment":1062},{"nctId":"NCT04401579","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 2 (ACTT-2)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-05-08","conditions":"COVID-19","enrollment":1033},{"nctId":"NCT04539262","phase":"PHASE1, PHASE2","title":"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2020-09-14","conditions":"COVID-19","enrollment":156},{"nctId":"NCT02818582","phase":"PHASE2","title":"GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2016-07-01","conditions":"Ebola","enrollment":38},{"nctId":"NCT04869579","phase":"PHASE2","title":"Selenium as a Potential Treatment for Moderately-ill, Severely-ill, and Critically-ill COVID-19 Patients.","status":"UNKNOWN","sponsor":"CHRISTUS Health","startDate":"2021-08-15","conditions":"Covid19","enrollment":100},{"nctId":"NCT04410354","phase":"PHASE2","title":"Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19","status":"TERMINATED","sponsor":"ViralClear Pharmaceuticals, Inc.","startDate":"2020-06-16","conditions":"COVID-19","enrollment":44},{"nctId":"NCT04480333","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831","status":"UNKNOWN","sponsor":"Biomed Industries, Inc.","startDate":"2020-09-15","conditions":"Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome","enrollment":45},{"nctId":"NCT04252664","phase":"PHASE3","title":"A Trial of Remdesivir in Adults With Mild and Moderate COVID-19","status":"SUSPENDED","sponsor":"Capital Medical University","startDate":"2020-02-12","conditions":"COVID-19, SARS-CoV-2","enrollment":308},{"nctId":"NCT04257656","phase":"PHASE3","title":"A Trial of Remdesivir in Adults With Severe COVID-19","status":"TERMINATED","sponsor":"Capital Medical University","startDate":"2020-02-06","conditions":"COVID-19, Remdesivir, SARS-CoV-2","enrollment":237}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo for remdesivir","genericName":"placebo for remdesivir","companyName":"Pfizer","companyId":"pfizer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in remdesivir clinical trials (likely COVID-19 or viral respiratory infection).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}